Kanada - francuski - Health Canada

bayer inc - loratadine - comprimé (à désintégration orale) - 5mg - loratadine 5mg - second generation antihistamines

Kanada - francuski - Health Canada

bayer inc - loratadine - comprimé (à désintégration orale) - 5mg - loratadine 5mg - second generation antihistamines

Švicarska - francuski - Swissmedic (Swiss Agency for Therapeutic Products)

bayer (schweiz) ag - sorafenibum - comprimés pelliculés - sorafenibum 200 mg à sorafenibi tosilas, cellulosum microcristallinum, carmellosum natricum seulement tenus ensemble, hypromellosum, magnésium stearas, natrii laurilsulfas, Überzug: hypromellosum, macrogolum 3350, e 171, e 172 (rouge), pour compresso haze corresp. sodium 0.275 mg. - le carcinome hépatocellulaire, carcinome carcinome différencié de la thyroïde - synthetika

Švicarska - francuski - Swissmedic (Swiss Agency for Therapeutic Products)

bayer (schweiz) ag - regorafenibum - comprimés pelliculés - regorafenibum 40 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 14.01 mg, magnesii stearas, povidonum, silica colloidalis anhydrica, Überzug: lecithinum ex soja, macrogolum 3350, poly(alcohol vinylicus), talcum, e 172 (rubrum), e 172 (flavum), e 171, pro compresso obducto. - metastasiertes de cancer colorectal, tumeurs stromales gastro-intestinales, carcinome hépatocellulaire - synthetika

Kanada - francuski - Health Canada

amgen canada inc - blinatumomab - poudre pour solution - 38.5mcg - blinatumomab 38.5mcg - antineoplastic agents

Švicarska - francuski - Swissmedic (Swiss Agency for Therapeutic Products)

pierre fabre pharma sa - encorafenibum - gélules - encorafenibum 50 mg, excipiens pro de la capsule. - melanom mit braf-v600-mutation in kombination mit binimetinib,; metastasiertes kolorektalkarzinom (crc) mit einer braf-v600e-mutation in kombination mit cetuximab - synthetika

Švicarska - francuski - Swissmedic (Swiss Agency for Therapeutic Products)

pierre fabre pharma sa - encorafenibum - gélules - encorafenibum 75 mg, excipiens pro de la capsule. - melanom mit braf-v600-mutation in kombination mit binimetinib,; metastasiertes kolorektalkarzinom (crc) mit einer braf-v600e-mutation in kombination mit cetuximab - synthetika

Europska Unija - francuski - EMA (European Medicines Agency)

amgen europe b.v. - blinatumomab - cellule précurseur leucémie lymphoblastique - lymphome - agents antinéoplasiques - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.

Kanada - francuski - Health Canada

eli lilly canada inc - olanzapine - comprimé (à désintégration orale) - 5mg - olanzapine 5mg - atypical antipsychotics

Kanada - francuski - Health Canada

eli lilly canada inc - olanzapine - comprimé (à désintégration orale) - 10mg - olanzapine 10mg - atypical antipsychotics